Curated news and analysis on clinical trials, drug approvals, and medical research.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.
A pan-cancer study identified 56 local cellular programs and 13 spatial niches across 12 cancer types. Multiple niches were linked to prognosis, immunotherapy response, and macrophage spatial distribution.
Phase III data showed dirozalkib improved progression-free survival and intracranial efficacy versus crizotinib in first-line ALK-positive advanced NSCLC. The drug received NMPA approval in August 2025.
Updated phase I data showed zoldonrasib produced a 52% confirmed objective response rate and 93% disease control rate in previously treated KRAS G12D-mutant NSCLC. No grade 4 or higher treatment-related adverse events were observed at the recommended phase II dose.
UAB researchers are advancing cancer prevention, tumor targeting and precision ablation, while AdvanCell is developing targeted alpha therapy and a prostate cancer drug in Phase 1 trials. Both efforts focus on new treatment approaches and research infrastructure.
Pfizer and Valneva said their investigational Lyme disease vaccine candidate showed more than 70% efficacy in the phase 3 VALOR trial. Pfizer plans regulatory submissions after the study, which reported no safety concerns at the time of analysis.
President Donald Trump said U.S. negotiators will meet Iran in Pakistan as Tehran says a proposed deal could be ready within days. The talks come while the Strait of Hormuz remains shut and Trump says limited strikes are possible.
The 12th Breakthrough Prizes were presented in Santa Monica, with six awards worth $3 million each. The prizes recognize research achievements in life sciences, fundamental physics and mathematics.
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.
Healthcare stocks were described as a defensive sector facing 2026 reimbursement headwinds, while capex rankings showed HCA Healthcare, Johnson & Johnson and Merck at the top. The sources also highlighted how capex differs across providers, device makers and drug developers.
A preclinical study in Cancer Letters found that pairing targeted treatments with CAR T-cell therapy may help control recurrence in triple-negative breast cancer. In laboratory and mouse models, the approach slowed tumor growth and reduced spread to the lungs and liver.
Cychlorphine has been detected in central Kentucky as Tennessee authorities link the synthetic opioid to 41 deaths in 11 counties in 2026. The drug is believed to be 10 times more potent than fentanyl and is not detectable by fentanyl testing strips.
UniQure shares fell sharply after FDA comments appeared to raise concerns about the invasive delivery method for Huntington's disease therapy AMT-130. The company had planned a 2026 BLA filing after Phase I/II data showed a 75% slowing of disease progression at 36 months.
Biopharma companies face a $275b patent cliff as licensing activity shifts toward China. China represented almost half of 2025 licensing activity and contributes about 30% of the global biotech pipeline.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
Rznomics said it will present interim AACR results for liver cancer candidate RZ-001 from a U.S. trial in patients with hepatocellular carcinoma. Tumor-shrinking responses were observed, and about 23% experienced complete disappearance of cancer cells.
Tango Therapeutics said it plans to start a pivotal 300-patient randomized vopimetostat trial in second-line pancreatic cancer this year after FDA interactions. The company also reported early combination enrollment with daraxonrasib and zoldonrasib and said more monotherapy and combination data are expected later this year.
Laurel police said four people were arrested and one more is wanted after a two-month-long drug investigation. Officers said they found heroin, cocaine, crack cocaine and a .38 caliber handgun at a Laurel apartment complex home.
The 2026 Dineen Cup Championship is set after Grand Junction beat Utah 2-1 to win the Mountain Division title on April 17. Grand Junction will face P.A.L. Junior Islanders, while South Shore will open against Idaho Falls.
